Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 111Neoplasms 8Neoplasm Metastasis 6Carcinoma, Intraductal, Noninfiltrating 6Breast Carcinoma In Situ 4Arthralgia 4Advanced Breast Cancer 4Osteoporosis 2Multiple Endocrine Neoplasia Type 1 2Breast Neoplasms, Male 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Sexual Dysfunction, Physiological 1Seizures 1Recurrence 1Quality of Life 1Patient Compliance 1Pain 1Ovarian Neoplasms 1Obesity 1Lethal Congenital Contracture Syndrome 2 1Joint Diseases 1Invasive Breast Cancer 1Hypogonadism 1Granulosa Cell Ovarian Cancer 1Fractures, Bone 1Erectile Dysfunction 1Epilepsy 1Bone Diseases, Metabolic 1Bone Density 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × Anastrozole × Clear all
NCT00181688 2012-12-05

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Massachusetts General Hospital

Phase 2 Completed
35 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡